Androstenedione
- TRADE NAMES: 4-androstene-3,17-dione; Androst-4-ene-3,17-dione
- INDICATIONS: Enhanced athletic performance, increased energy, to keep red blood cells healthy
- SYNONYM: N/A
- CLASS: Aromatase inhibitor
- HALF-LIFE: N/A
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
Protease inhibitors cause dyslipidemia which includes elevated triglycerides and cholesterol and redistribution of body fat centrally to produce the so-called "protease paunch", breast enlargement, facial atrophy, and "buffalo hump"
In 2004 the FDA requested companies to stop distributing products containing androstenedione. Studies have shown that it does not increase muscle mass and that it poses the same kind of health risks as anabolic steroids, including abnormal elevations in serum estrogen, increased risk of prostate, pancreatic and endometrial cancers, and increased cardiovascular disease risk.
Please login to see the rest of this drug profile
SKIN.
HAIR.
GENITOURINARY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric